Rucaparib in BAP1-Deficient or BRCA1-Deficient Mesothelioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rucaparib in Patients With BAP1-Deficient or BRCA1-Deficient Mesothelioma (MiST1): An Open-Label, Single-Arm, Phase 2a Clinical Trial
Lancet Respir Med 2021 Jan 27;[EPub Ahead of Print], DA Fennell, A King, S Mohammed, A Branson, C Brookes, L Darlison, AG Dawson, A Gaba, M Hutka, B Morgan, A Nicholson, C Richards, P Wells-Jordan, GJ Murphy, A ThomasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.